Leading the Way in Life Science Technologies

GEN Exclusives

More »

February 15, Vol. 30, No. 4

  • Feature Articles

    • Refined Tools Aid in Pathway Analysis
    • Elizabeth Lipp
    • As pharma looks for better ways to build its drug pipelines, researchers are improving upon existing technologies and broadening their usage At CHI’s recent “High Content Analysis” conference, presenters discussed new and revamped tools, and showed how these advances are ... more »
    • Contract Manufacturing Bucks Economic Downturn
    • Eric S. Langer
    • The biopharmaceutical industry’s capacity pendulum has taken wide swings over the past decade—from shortfall to overcapacity—as companies built up production for projected pipeline products that failed to materialize In the ramping-up process, the industry has made major investments in facilities, ... more »
    • Insights Mount on Copy Number Variants
    • Richard A. Stein
    • Until recently, single nucleotide polymorphisms (SNPs) were thought to represent the only source of inter-individual variation at the genome level Subsequently, it became apparent that different individuals may harbor various copy numbers of certain genes or genomic regions... more »
    • Trends in Monoclonal Antibody Production
    • Gail Dutton
    • In the decade since severe capacity constraints limited monoclonal antibody (mAb) production, the industry has adjusted, so that today, overcapacity is the issue, along with developing techniques to ensure product quality, reduce development timelines, and decrease costs Many of these ... more »
    • Preparing for the Next Influenza Pandemic
    • Gail Dutton
    • Since the H1N1 strain of influenza emerged last spring, there has been a flurry of activity to find strategies to treat the strain more effectively, to make doses of existing therapeutics go further, and to develop new vaccines more quickly ... more »
    • Induced Pluripotent Stem Cell Overview
    • Vi Chu
    • The ability to reprogram somatic cells to generate induced pluripotent stem (iPS) cells has generated tremendous interest and discussion since iPS cells were first produced from mouse cells in 2006 and human cells in 2007... more »
  • Columns

    • Whistle-Blower Protection a Must
    • Jonathan Rackoff
    • In November 2008, Suzanne Stratton, PhD, was summarily dismissed from her job at the Carle Foundation Hospital in Urbana, ILThe events leading up to her firing, those currently known, paint a chilling picture of rogue research, an institutional culture unwilling ... more »
    • Companion Diagnostic Reimbursement
    • Jonathan Witonsky
    • Companion diagnostic tests enable physicians to recommend safer and more effective treatment plans where therapeutic selection is based on the genetic makeup of the patient Many companies are eager to participate in the currently nascent companion diagnostics market; there is ... more »
  • Tutorials

    • Predicting Drug-Induced Myelotoxicity
    • Emer Clarke
      Eric Atkinson
    • Potential pharmaceuticals are typically screened for toxicity with high-throughput assays that utilize cultured cell lines and simple endpoints like cell death or inhibition of cell proliferation Although these methods have allowed the screening of huge numbers of compounds with millions ... more »
    • Tips on Buying and Working with Luciferin
    • Scott Mohler
    • Luciferin is the basic substrate of bioluminescent assays Based on a simple reaction where ATP fuels luciferase catalysis of firefly (beetle) luciferin to produce light, bioluminescence has broad applications Its employment as a biomass indicator allows for the detection of ... more »